Item 7.01. Regulation FD.
On September 8, 2021, Motus GI Holdings, Inc. (the "Company") issued a press
release announcing enrollment of patients at a second site in the European Union
(EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in
patients with a history of poor bowel preparation using a low volume preparation
with limited diet restrictions and the Pure-Vu System. A copy of the press
release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01, including
the information contained in Exhibit 99.1, is being furnished to the Securities
and Exchange Commission, and shall not be deemed to be "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, and shall not be
deemed to be incorporated by reference into any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by a specific reference in such filing.
Item 8.01 Other Events.
On September 8, 2021, the Company announced the enrollment of patients at
GastroZentrum Lippe, a private endoscopy clinic in Germany, the second site for
the Company's European Union (EU) study of the Pure-Vu System, which is
evaluating the clinical outcomes in patients with a history of poor bowel
preparation using a low volume preparation with limited diet restrictions and
the Pure-Vu System.
Germany is currently the largest colonoscopy market in Europe, with
approximately 1.7 million procedures expected to be performed in 2021, according
to iData Research Inc.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibit is furnished with this report:
Exhibit No. Description
99.1 Press Release issued by Motus GI Holdings, Inc., dated September 8, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses